These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 18237829)
1. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Newman PA; Daley A; Halpenny R; Loutfy M Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829 [TBL] [Abstract][Full Text] [Related]
2. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Newman PA; Roungprakhon S; Tepjan S; Yim S Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897 [TBL] [Abstract][Full Text] [Related]
3. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Allen M; Lau CY Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272 [TBL] [Abstract][Full Text] [Related]
4. Community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Olin J; Kokolamami J; Lepira FB; Mwandagalirwa K; Mupenda B; Ndongala ML; Maman S; Bollinger R; Nachega J; Mokili J Cult Health Sex; 2006; 8(6):529-44. PubMed ID: 17050384 [TBL] [Abstract][Full Text] [Related]
5. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. Harrison K; Vlahov D; Jones K; Charron K; Clements ML J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):386-90. PubMed ID: 7552502 [TBL] [Abstract][Full Text] [Related]
6. [The psychosocial approach to the planning and implementation of vaccine trials for HIV infection]. Starace F; Embrione F; Fusco ML; Cafaro L Ann Ist Super Sanita; 2003; 39(2):259-66. PubMed ID: 14587226 [TBL] [Abstract][Full Text] [Related]
7. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. Rudy ET; Newman PA; Duan N; Kelly EM; Roberts KJ; Seiden DS AIDS Educ Prev; 2005 Jun; 17(3):253-67. PubMed ID: 16006211 [TBL] [Abstract][Full Text] [Related]
8. Social and behavioral science in HIV vaccine trials: a gap assessment of the literature. Lau CY; Stansbury JP; Gust DA; Kafaar Z Expert Rev Vaccines; 2009 Feb; 8(2):179-90. PubMed ID: 19196198 [TBL] [Abstract][Full Text] [Related]
9. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. Chesney MA; Lurie P; Coates TJ J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232 [No Abstract] [Full Text] [Related]
10. Interest in HIV vaccines among injection drug users in Baltimore, Maryland. Vlahov D; Astemborski J; Solomon L; Galai N; Basarab L; Nelson KE AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S265-8. PubMed ID: 7865315 [TBL] [Abstract][Full Text] [Related]
11. Correlates of HIV vaccine trial participation: an Indian perspective. Sahay S; Mehendale S; Sane S; Brahme R; Brown A; Charron K; Beyrer C; Bollinger R; Paranjape R Vaccine; 2005 Feb; 23(11):1351-8. PubMed ID: 15661383 [TBL] [Abstract][Full Text] [Related]
12. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. MacQueen KM; Buchbinder S; Douglas JM; Judson FN; McKirnan DJ; Bartholow B AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314 [No Abstract] [Full Text] [Related]
13. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. Pitisuttithum P; Choopanya K; Bussaratid V; Vanichseni S; van Griensven F; Phonrat B; Martin M; Vimutsunthorn E; Sangkum U; Kitayaporn D; Tappero JW; Heyward W; Francis D J Med Assoc Thai; 2007 Nov; 90(11):2442-8. PubMed ID: 18181333 [TBL] [Abstract][Full Text] [Related]
14. Incentives and disincentives to participate in prophylactic HIV vaccine research. Jenkins RA; Temoshok LR; Virochsiri K J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):36-42. PubMed ID: 7712233 [TBL] [Abstract][Full Text] [Related]
16. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. Luzi AM; Gallo P; Colucci A; Marcotullio S; Bellino S; Longo O; Ensoli B AIDS Care; 2011 Aug; 23(8):939-46. PubMed ID: 21390884 [TBL] [Abstract][Full Text] [Related]
17. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand. Thapinta D; Jenkins RA Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444 [TBL] [Abstract][Full Text] [Related]
18. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. Temoshok LR AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318 [No Abstract] [Full Text] [Related]
19. A small dose of HIV? HIV vaccine mental models and risk communication. Newman PA; Seiden DS; Roberts KJ; Kakinami L; Duan N Health Educ Behav; 2009 Apr; 36(2):321-33. PubMed ID: 18032589 [TBL] [Abstract][Full Text] [Related]
20. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. Brooks RA; Newman PA; Duan N; Ortiz DJ AIDS Care; 2007 Jan; 19(1):52-8. PubMed ID: 17129857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]